Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.

MoonLake Immunotherapeutics (NASDAQ:MLTX) develops the tri-specific nanobody Sonelokimab (SLK), a chemical that targets and penetrates difficult-to-reach inflammatory regions.

MoonLake has recently announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) the E.U. European Medicines Agency (EMA), with both ...

MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for hidradenitis suppurativa (HS) is expected. Read the full report.

ZUG, Switzerland, July 25, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory ...

MoonLake Immunotherapeutics Media & Investors Relations . Carla Bretes, Director IR & External Communications. [email protected]. ICR Healthcare . Mary-Jane Elliott, Namrata Taak, Ashley Tapp.

MoonLake Immunotherapeutics AG. New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase ...

MoonLake Immunotherapeutics AG. MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update. Ended the third quarter with $493.9 million in cash, cash ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar ...